Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.

Catharina BuschDinah ZurSamantha Fraser-BellInês LaínsAna Rita SantosMarco LupidiCarlo CaginiPierre-Henry GabrielleAude CouturierValérie Mané-TautyErmete GiancipoliGiuseppe D'Amico RicciZafer CebeciPatricio J Rodríguez-ValdésVoraporn ChaikitmongkolAtchara AmphornphruetIsaac HindiKushal AgrawalJay ChhablaniAnat LoewensteinMatias IglickiMatus Rehaknull null

Published in: Acta diabetologica (2018)

In a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy.

Keyphrases

vascular endothelial growth factor
endothelial cells
low dose
metabolic syndrome
soft tissue
optical coherence tomography
skeletal muscle
adipose tissue
high dose
insulin resistance
bone marrow
ultrasound guided